Member Info for mazik

Ahfam3 true we have £2 million, sure hoping RNS that we are selected for Agile than surely will have funds from the government to promote our much needed technology .

Sareum is currently investigating SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in a preclinical Covid-19 research programme. The programme, which commenced in December 2020 with grant funding from the UK government, is expected to take approximately six months to complete and aims to investigate the effects of SDC-1801 on cytokine signalling after human cells are infected with SARS-CoV-2, to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease. The Company is also investigating whether treatment with SDC-1801 in disease models can re-establish protection against bacterial pneumonia following SARS-CoV-2 infection.

The Company has previously stated it would require additional funding to advance SDC-1801 into clinical trials depending both on positive results from its ongoing Covid-19 research programme and on the successful outcome of the Company's broader preclinical development programme with SDC-1801. The Company believes that, should the current preclinical work programme be successful and indicate that SDC-1801 is a potential treatment for severe-phase Covid-19, the Company may be eligible for an AGILE grant. Further update is imminent with rerate its SP to more like 20p in the making of a big setup like Halozyme in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones. Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialised medicines using the technology.

Enormous potential cannot be ignored on of many in front of us "SRA737 was discovered and initially developed by scientists at The ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a c.$300 million plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement."

All in the press, could Sareum be in the list for a takeover?

Sareum is well placed " The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Market Cap of £500m as a starter translates 20p as a starter.IMO

Out they go with their 10% profit :-)

Num4 thanks for sharing your research , patience for reward..

Agile inclusion looks mandatory imo, that will surely continue the journey north with biotrinity 21 presentation held today...surely expect rms of its content..my opinion GSK could surprise us or other across the pond..20/25p

Large trades feel Instituitions are accumulating or a predator on our wings

Boilb good luck, my 500k shares tucked and locked in safe in my ISA all funds used until I get £20k allocation for this years ISA...Sareum holders hold tight and IMO

Fearg thank u for your feedback....onwards and upwards..gla

Hope the likes of GSK takes a swipe at Sareum and we all benefit ...hold and add..this will reward us for our retirement.

Gsk are more likely predators at the moment, they have the appetite have made 13 acquisitions and 39 investments spent over $15.8 billion and has invested in multiple sectors like infectious diseases, oncology, immunology and more. Sareum will fit the bill as an investment or a takeover..imo

Bobbler thanks for your feedback, I trust the science here I am with the LTH...feel confident once in a life time opportunity cannot be missed. GLA

Good morning thanks for sharing your research material sadoldgit.....have a good day onward and upwards...

James lucky to be in, as yesterday afternoon showing less value only logical move was to top up...stressful hope today is going to be good day..Gla

Sadoldgit thanks for sharing your research..Today the mm's squeezed shares out the shares from many LTH...and forced them to sell with manipulative swings....Tomorrow will be very positive start..

Ahfam thanks for your feedback and feel that it might go back to this weeks high in par with u

JAK1/JAK3 inhibitor] Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia https://t.co/gK41kwSnvT
"In this trial, among hospitalized adult patients with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure"
$SAR.L Sareum #TYK2 #Covid-19

Patience was needed this morning, many topped up at bargain basement price , I was not that clever but got 300k below 7p...hold for gold...this share is not for faint hearted...